Skip to main content
Download PDF

MicroRNA-378a-3p prevents initiation and growth of colorectal cancer by fine tuning polyamine synthesis

Cell & Bioscience volume 12, Article number: 192 (2022) Cite this article

Abstract

Background

Inhibitors of ornithine decarboxylase (ODC) are effective at preventing colorectal cancer (CRC). However, their high toxicity limits their clinical application. This study was aimed to explore the potential of microRNAs (miRNAs) as an inhibitor of ODC.

Methods

miRNA array was used to identify dysregulated miRNAs in CRC tumors of mice and patients. Azoxymethane (AOM)/Dextran Sodium Sulfate (DSS) were used to induce CRC in mice. miRNA function in carcinogenesis was determined by soft-agar colony formation, flow cytometry, and wound healing of CRC cells. Mini-circle was used to deliver miRNA into colons.

Results

MiRNA profiling identified miR-378a-3p (miR-378a) as the most reduced miRNA in CRC tumors of patients and mice treated with AOM/DSS. Pathway array analysis revealed that miR-378a impaired c-MYC and ODC1 pathways. Further studies identified FOXQ1 (forkhead box Q1) and ODC1 as two direct targets of miR-378a. FOXQ1 activated transcription of c-MYC, a transcription activator of ODC1. In addition to directly targeting ODC1, miR-378a also inhibited expression of ODC1 via the FOXQ1-cMYC axis, thereby inhibiting polyamine synthesis in human CRC cells. Phenotypically, by reducing polyamine synthesis, miR-378a induced apoptosis and inhibited proliferation and migration of CRC cells, while disrupting the association of miR-378a with FOXQ1 and ODC1 offset the effects of miR-378a, suggesting that FOXQ1 and ODC1 were required for miR-378a to inhibit CRC cell growth. MiR-378a treatment robustly prevented growth of HCC by inhibiting polyamine synthesis in AOM/DSS mice.

Conclusion

MiR-378a prevents CRC by inhibiting polyamine synthesis, suggesting its use as a novel ODC inhibitor against CRC.

Background

Colorectal cancer (CRC) is the second leading cause of cancer-related death worldwide [1, 2]. Despite the improvement of current treatment strategies including surgical resection, radiotherapy and chemotherapy, 5-year overall survival rate of patients with CRC in U.S is roughly 65% because of tumor recurrence and/or metastasis [2, 3]. Therefore, it is imperative to perform a comprehensive understanding of molecular variables that control pathways involved in colon carcinogenesis and identify new and effective therapeutic agents with minimal adverse effects and toxicity to other organs.

Many molecular drivers of CRC have been reported over the years and some therapeutic agents based on these drivers have entered into clinical trials [4]. ODC1, the rate-limiting enzyme in polyamine synthesis, is another new and important therapeutic target for the treatment of CRC [5]. Polyamines are a class of small polycationic metabolites that are involved in cell growth and proliferation [6]. Although ODC1 activity is required for normal growth, it is elevated in many types of human cancers such as CRC and liver cancer [7]. In cancer, polyamine synthesis is increased primarily due to activation of polyamine biosynthetic enzymes [6, 8], which drives malignant transformation of cells and tumor progression. Activation of polyamine biosynthesis is controlled by multiple oncogenic pathways including RAS and c-MYC [9]. These oncogenic events frequently occur in CRC [10]. Polyamine synthesis is heavily regulated by c-MYC. c-MYC is able to activate expression of genes controlling polyamine synthesis including ODC1. [11] Inhibitors of polyamine synthesis and polyamine transport have been tested in preclinical and clinical studies [6, 8]. Despite some promising observations during the clinical trial, polyamine inhibitors have generally been proven to be disappointing [11, 14], except for difluoromethylornithine (DFMO) that is effective at preventing recurrent CRC [12, 13]. However, DFMO has severe side effects including hearing loss [14], which limits its clinical application.

MicroRNAs (miRNAs) are a class of small non-coding RNAs that function by binding to the 3'-untranslated regions (3'-UTR) of specific mRNAs, which leads to mRNA cleavage or translational repression [15, 16]. miRNAs fine-tune gene expression in mammalian cells to maintain physiological homeostasis. This exquisite ability of miRNAs makes them an ideal candidate regulator to precisely modulate level of polyamines to prevent initiation of CRC but still meet the needs for growth of normal cells. By comparing miRNA profile of CRC patients and normal individuals, we identified miR-378a as the most downregulated in both human and mouse CRC. Further studies revealed that miR-378a was an inhibitor of polyamine synthesis by modulating the FOXQ1-cMYC-ODC1 axis. In this study, we tested the hypothesis that miR-378a prevents CRC development by repressing overproduction of polyamine.

Results

MiR-378a is the most reduced miRNA in CRC tumors of patients and AOM/DSS mice.

CRCs arise from one or a combination of three different mechanisms, namely chromosomal instability (CIN), CpG island methylator phenotype (CIMP), and/or microsatellite instability (MSI) [4]. Most of the miRome studies on colon cancer focus on the colon tumor and adjacent non-tumor tissue [17,18,19]. Such a strategy only identified differentially expressed miRNAs triggered by CIN, CIMP or MSI since cells from both cancerous colon tissues and adjacent normal tissues have the same genome DNA. Importantly, the procedure of tumor resection is a potentially strong contributor to the variability of data among different studies, indicating that it is important to compare miRNAs between CRC patients and normal individuals. Previously, we have identified 37 differentially-expressed miRNAs in 80 colon tumors compared to 28 normal mucosa samples [20]. We further analyzed miRNA profiles from normal colon tissues and CRC tumors from AOM/DSS mice and identified 54 differentially-expressed miRNA (Fig. 1A) [21]. To identify miRNAs that are altered in CRC tumors of both patients and mice, we correlated altered 54 miRNAs in AOM/DSS mice with 37 miRNAs that are differentially-expressed in CRC patients [20]. This correlation analysis identified four miRNAs that were downregulated in both human and mouse CRC tumors (Fig. 1B). miR-378a-3p (miR-378a) was identified as the most reduced among four under-expressed miRNAs in CRC tumor, leading us to focus on miR-378a. qRT-PCR analysis of 28 normal colon tissues and 80 colon tumors further validated that miR-378a expression was robustly reduced in colon tumors versus normal colon tissues (Fig. 1C).

Fig. 1
figure 1

miR-378a is reduced in CRC tumors of patients and AOM/DSS mice. A 54 differentially expressed miRNAs in CRC tumors of AOM/DSS mice (n = 3). Normal colons from wild-type mice (n = 3) served as the control. Fold change ≥ 2 and p ≤ 0.05. B Four miRNAs that are reduced in CRC tumors of patients and AOM/DSS mice. C qRT-PCR confirming that miR-378a was significantly reduced in 80 CRC tumors versus 28 normal colon tissues. D Reduced expression of Mdm2, Odc1, c-Myc, Tfrc, and Vcam1 in mouse colorectal cancer CT26.WT cells. Oligo Signal Transduction PathwayFinder MicroArray (Qiagen) was used to identify signaling pathways altered by miR-378a. E, F Reduced mRNA levels of c-MYC and ODC1 in 275 CRC tumors versus 41 normal colon tissues in TCGA database. TPM: transcripts per million. Expression levels were shown as Log2 (TPM + 1). P-value was determined by DEseq. Data represent mean ± SEM. *p < 0.05 (A–C: two-tailed student’s t test)

Full size image

To determine the role of miR-378a in regulating CRC, we overexpressed miR-378a in mouse colorectal adenocarcinoma CT26.WT cells and determined expression of 117 genes related to the onset, development, and progression of tumorigenesis using the Signal Transduction PathwayFinder MicroArray (Qiagen). For this purpose, we constructed an expression vector of miR-378a by cloning miR-378a precursor into mini-circle vectors (MC). MCs are episomal DNA vectors that are produced as circular expression cassettes devoid of any bacterial plasmid DNA backbone [22]. Their small molecular size enables more efficient delivery and offers sustained expression over several weeks compared to standard plasmid vectors that only express for a few days after injection into mice [22]. This vector was referred to as MC-miR378. To rule out a non-specific effect of the plasmid, we generated a miR-378a mis-matched-expression vector by mutating the seed region of miR-378a (MC-miR378-MM). Transfection of MC-miR378 into CT26.WT cells significantly inhibited expression of five genes including Mdm2 (mouse double minute 2 homolog), Odc1, c-Myc, Tfrc (transferrin receptor 1) and Vcam1 (vascular cell adhesion molecule-1) (Fig. 1D). Among five genes reduced by miR-378a, no significant change in levels of MDM2, TFRC, and VCAM1 was observed in human CRC tumors (n = 275) versus normal colon specimen (n = 41) from TCGA database (Additional file 1: Fig. S1A–C), while levels of c-MYC and ODC1 were significantly increased (Fig. 1E, F). In summary, level of miR-378a is inversely correlated with mRNA levels of ODC1 and c-MYC in both human and mouse CRC tumors.

miR-378a inhibits expression of ODC1 by binding to its 3’UTR

It is known that dysregulated activities of ODC1 and c-MYC are important promoters of CRC. We, therefore, hypothesized that miR-378a was a potential tumor suppressor by repressing ODC1 and c-MYC expression. We next determined the molecular mechanism by which miR-378a inhibits expression of ODC1 and c-MYC. Combining bioinformatic prediction and mining of Ago HITS-CLIP database (high-throughput sequencing of RNAs isolated by crosslinking immunoprecipitation from argonaute protein complex) [23], we identified a conserved binding site of miR-378a within the 3’UTR of ODC1 (Fig. 2A). Consistent with reduced miR-378a, expression of Odc1 was significantly increased in CRC tumors of AOM/DSS mice (Fig. 2B). To determine if miR-378a inhibits Odc1 directly by binding to the 3’UTR of Odc1, a luciferase reporter was employed, in which the 3’UTR containing wild-type or mutated miR-378a binding site was embedded into the downstream of the luciferase. Indeed, the luciferase activity was reduced by miR-378a in HCT116 cells (Fig. 2C), whereas mutation of the miR-378a binding site within the 3’UTR of Odc1 impaired the ability of miR-378a to reduce luciferase activity (Fig. 2C), suggesting the direct repression of miR-378a on Odc1. Injection of miR-378a into mice also repressed mRNA and protein levels of Odc1 (Fig. 2D). In human DLD-1 cells, overexpression of miR-378a led to reduced mRNA and protein levels of c-MYC and ODC1 (Fig. 2E). In summary, miR-378a is able to inhibit expression of both murine and human ODC1 by binding to their 3’UTRs.

Fig. 2
figure 2

miR-378a inhibits expression of Odc1 via binding to its 3’UTR. A Graphic representation of the conserved miR-378a binding motif within the 3’UTRs of ODC1 between human and mouse. B mRNA levels of Odc1 in CRC tumors of AOM/DSS mice (n = 6) and normal colon tissues of WT mice (n = 6). C miR-378 significantly reduced luciferase activity of the luciferase reporter construct containing the 3’UTR of Odc1 with either wild-type or mutated miR-378a binding site. Mutation of the miR-378 binding site within the 3’UTR of Odc1 canceled the ability of miR-378a to inhibit luciferase activity. D mRNA and protein levels of Odc1 in AOM/DSS mice injected with MC-miR378 or MC-miR378-MM (MM, control). FC: fold change. E mRNA and protein levels of ODC1 and c-MYC in DLD-1 cells transfected with MC-miR378 or MC-miR378-MM. FC: fold change. Data represent mean ± SEM. **p < 0.01, ns: no significance (B–E: two-tailed student’s t test)

Full size image

MiR-378a indirectly inhibits expression of c-MYC by inhibiting FOXQ1.

Although miR-378a significantly inhibited expression of c-MYC (Fig. 1D), no binding motif for miR-378a was identified within the 3'UTR of c-MYC. Luciferase assay confirmed that miR-378a had no binding site within the 3’UTR of c-MYC (Additional file 1: Fig. S2A, B). We, therefore, speculated that miR-378a inhibited transcription of c-MYC expression via directly targeting a transcription activator that has a binding site within the promoter of c-MYC. To test this speculation, we used MatInspector software to scan the promoter of c-MYC and identified a highly conserved binding motif for FOXQ1 (Fig. 3A) [24]. FOXQ1 is an oncogenic transcription factor that binds to GTTT core motif [25]. Furthermore, combining bioinformatic prediction and mining of Ago HITS-CLIP database, we identified a potential binding site of miR-378a within the 3’UTR of FOXQ1 (Fig. 3B). Level of FOXQ1 was increased in CRC patients (Fig. 3C). These findings led us to speculate that miR-378a inhibited expression of c-MYC by repressing transcription of FOXQ1 (Fig. 3A). miR-378a significantly reduced luciferase activity of the construct containing the 3’UTR of FOXQ1, whereas disrupting the interaction between miR-378a and FOXQ1 by mutating miR-378a binding site prevented miR-378a from repressing luciferase activity (Fig. 3D). Overexpression of miR-378a in DLD-1 cells reduced mRNA and protein levels of FOXQ1 and c-MYC (Fig. 3E). In murine CT26.WT cells, overexpression of miR-378a significantly inhibited expression of FoxQ1 and c-Myc (Fig. 3F). Together, FOXQ1 is a direct target of miR-378a.

Fig. 3
figure 3

miR-378a inhibits c-MYC transcription by directly targeting FOXQ1. A A proposed mechanism by which miR-378a inhibits transcription of c-MYC by directly targeting FOXQ1 that serves as a transcription activator of c-MYC. B The predicted miR-378a binding motif within the 3’UTRs of human and mouse FOXQ1. C mRNA levels of FOXQ1 in CRC tumors of 275 patients versus 41 normal colon tissues in TCGA database. TPM: transcripts per million. Expression levels were shown as Log2 (TPM + 1). P-value was determined by DEseq. D Luciferase activities of the reporter constructs containing the 3’UTR of FoxQ1 with either WT or mutated miR-378a binding site after treatment with MC-miR378. HCT116 cells transfected with the luciferase reporter vector and MC-miR378-MM served as a control. E mRNA and protein levels of FOXQ1 and c-MYC in DLD-1 cells transfected with MC-miR378 or MC-miR-378-MM (control). FC: fold change. F Protein and mRNA levels of FoxQ1 and c-Myc in CT26.WT cells transfected with MC-miR378 or MC-miR-378-MM (control). FC: fold change. Data represent mean ± SEM. **p < 0.01, and ns: no significance (D–F two-tailed student’s t test)

Full size image

We next determined if FOXQ1 was a transcription activator of c-MYC. Luciferase assay was used to evaluate if FOXQ1 was able to inhibit transcription of c-MYC. Overexpression of FOXQ1 significantly increased activity of the c-MYC promoter (Fig. 4A). To determine if the binding site for FOXQ1 within the c-MYC promoter was required for increased expression of c-MYC, we mutated the FOXQ1 binding site within the c-MYC promoter. As expected, this mutation prevented FOXQ1 from driving transcription of c-MYC (Fig. 4A). Overexpression of FOXQ1 strongly enhanced transcription of both c-MYC and ODC1 in DLD-1 cells (Fig. 4B). Overexpression of FoxQ1 in mouse colon cells lead to increased c-Myc and Odc1 (Fig. 4C). As revealed by chromatin immunoprecipitation (ChIP), DNA fragments containing FOXQ1 binding motif within the c-MYC promoter were immune-precipitated from genomic DNA from DLD-1 cells by an FOXQ1 antibody (Fig. 4D), suggesting that FOXQ1 was able to physically bind to the promoter of c-MYC. Delivery of miR-378a into mice reduced mRNA levels of FoxQ1 and c-Myc (Fig. 4E). Our hypothesis is that miR-378a inhibits polyamine synthesis by directly targeting ODC1 and blocking the FOXQ1-MYC-ODC1 axis. We next measured the effect of miR-378a on levels of polyamine in DLD-1 and HCT116 cells. As expected, miR-378a significantly reduced spermine (SPM), putrescine (PUT), and spermidine (SPD) in DLD-1 and HCT116 cells (Fig. 4F). In summary, FOXQ1 is a transcription activator of c-MYC. miR-378a inhibited polyamine synthesis by directly repressing ODC1 and blocking the FOXQ1-c-MYC-ODC1 signaling.

Fig. 4
figure 4

FOXQ1 activates transcription of c-MYC. A Luciferase activity of the reporter construct containing c-MYC promoter with either WT or mutated FOXQ1 binding site after treatment with FOXQ1 expression vector or empty vector (control). B mRNA levels of c-MYC and ODC1 in DLD-1 cells transfected with FOXQ1 expression vector or empty vector (control). C mRNA levels of c-Myc and Odc1 in CT26.WT cells transfected with FoxQ1 expression vector or empty vector (control). D ChIP assay was performed using genomic DNA isolated from DLD-1 cells; and the binding of FOXQ1 to the endogenous promoter of c-MYC was detected using an FOXQ1 antibody; N.S.: non-specific control, which is located 10 kb downstream of the predicted FOXQ1 binding site. E mRNA levels of c-Myc and Odc1 in AOM/DSS mice injected with MC-miR378 or MC-miR378-MM (MM, control). F Levels of putrescine (PUT), spermidine (SPD) and spermine (SPM) in DLD-1 and HCT116 cells after transfection of MC-miR378 or MC-miR378-MM (control). Data represent mean ± SEM. **p < 0.01, ***p < 0.001, and ns: no significance (A–C, E, F: two-tailed student’s t test; D: two-way ANOVA test)

Full size image

MiR-378a inhibited growth and proliferation of CRC cells via inhibiting polyamine synthesis.

To determine the role of miR-378a in tumorigenesis of CRC, we overexpressed miR-378a in DLD-1 cells, which led to reduced mRNA levels of FOXQ1 and ODC1 (Additional file 1: Fig. S3A). Overexpression of miR-378a significantly reduced ODC activity in DLD-1 cells and polyamine synthesis (Fig. 5A, Additional file 1: Fig. S3B), which subsequently inhibited their growth and viability, as revealed by colony formation and MTT assay (Fig. 5B, C). In addition to inhibiting proliferation and migration, miR-378a also significantly induced apoptosis and death of DLD-1 cells (Fig. 5D). Would healing assay further validated the inhibitory effect of miR-378a on growth of DLD-1 cells (Fig. 5E).

Fig. 5
figure 5

ODC1 mediates the role of miR-378a in inhibiting proliferation and growth and inducing apoptosis of CRC cells. A Enzyme activity of ODC in DLD-1 cells transfected with MC-miR378 or MC-miR378-MM (control). B Soft agar colony formation assay revealed that miR-378a overexpression inhibited growth and viability of DLD-1 cells. DLD-1 cells were transfected with MC-miR378 or MC-miR378-MM (control). C Reduced viability of DLD-1 cells after MC-miR378 transfection, as revealed by MTT assay. DLD-1 cells treated with MC-miR378-MM served as the control. D miR-378a induced apoptosis of DLD-1 cells, as revealed by flow cytometry. A statistical graph of Annexin V-FITC/PI staining is shown. E Wound healing showing that miR-378a significantly impaired growth and migration of DLD-1 cells. F miR-378a treatment reduced ODC enzyme activity, while additional treatment of TPs of ODC1 and FOXQ1 impaired the ability of miR-378a to inhibit ODC activity. Three groups of DLD-1 cells were transfected with MC-miR378-MM (control), MC-miR378, or a combination of MC-miR378 and TPs of ODC1 and FOXQ1. G miR-378a reduced proliferation and growth of DLD1 cells and induced apoptosis of DLD1 cells, while additional treatment of TPs of FOXQ1 and ODC1 counteracted the ability of miR-378a to repress proliferation and growth and induce apoptosis of DLD-1 cells, as revealed by Wound Healing, MTT assay, and flow cytometry analysis, respectively. Data represent mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001 (A–E: two-tailed student’s t test, F–G: two-way ANOVA test)

Full size image

MiR-378a targets many genes simultaneously. We next determined whether the FOXQ1-MYC-ODC1-mediated polyamine synthesis, at least in part, was responsible for miR-378a to inhibit proliferation and induce apoptosis. For this purpose, we used a novel technique Target Protector morpholinos (TP) to prevent the interaction of miR-378a with FOXQ1 and ODC1. [26] The morpholinos were complimentary to the miR-378a binding sites present within the 3’UTRs of FOXQ1 and ODC1 mRNAs, thereby preventing miR-378a from binding to the 3’UTRs of FOXQ1 and ODC1. Specifically, three groups of DLD-1 cells were transfected with MC-miR378-MM, MC-miR-378 or a combination of MC-miR-378 and TPs of ODC1 and FOXQ1. Overexpression of miR-378a reduced expression of FOXQ1 and ODC1, while additional treatment of TPs of FOXQ1 and ODC1 impaired the ability of miR-378a to prevent their expression (Additional file 1: Fig. S3C). MiR-378a treatment reduced ODC activity and polyamine synthesis, while additional treatment of FOXQ1 and ODC1 TPs offset the effects of miR-378a (Fig. 5F, Additional file 1: Fig. S3D). Treatment of FOXQ1 and ODC1 TPs, which disrupted the interaction between miR-378a and 3’UTRs of FOXQ1 and ODC1, impaired the ability of miR-378a to inhibit proliferation and migration and induce apoptosis of DLD-1 cells (Fig. 5G). In sum, the FOXQ1-MYC-ODC1 axis mediates the roles of miR-378a in inhibiting polyamine synthesis, preventing proliferation and growth, and inducing apoptosis of CRC cells.

MiR-378a prevented overproduction of polyamine and growth of CRC in AOM/DSS mice

Carcinogen-induced colon cancer in mice simulates the phases of initiation and progression of tumor that occur in humans [27]. To evaluate the potential of miR-378a to inhibit CRC in vivo, we exposed mice to AOM and DSS to induce CRC (Fig. 6A). [27] The AOM/DSS mice recapitulate a chemical-induced carcinogenesis, inflammatory effects, colitis-driven initiation stage and sequential tumor progression [27]. Therefore, we next determined gain-of miR-378a function against CRC in AOM/DSS mice. The small molecular size of MCs enables efficient delivery and offers a sustained expression for a few weeks, as described above. We therefore used MC-miR378, as diagramed in Fig. 6B, to overexpress miR-378a in mice. Two groups of AOM/DSS mice were injected with either MC-miR378-MM (control) or MC-miR378 at a dose of 2.5 μg/g by tail vein weekly for ten weeks. Injection of MC-miR378 into AOM/DSS mice led to increased miR-378a in the colon (Additional file 1: Fig. S4). MiR-378a treatment resulted in a significant reduction in tumor size and number (Fig. 6C). We next performed the histopathological evaluation of intestinal inflammation, hyperplasia and tumorigenicity using H&E staining. Consistent with previous reports [28], diffuse mucosal hyperplasia was observed in the distal colon of AOM/DSS mice (control) (Fig. 6D). In contrast, no or much less hyperplasia was observed in the colonic mucosae of AOM/DSS mice treated with miR-378a (Fig. 6D). Inflammation is a major driver of CRC development in AOM/DSS mice. A significant reduction in inflammation and hyperplasia score was observed in miR-378a-treated AOM/DSS mice (Fig. 6E). MiR-378a treatment also reduced adenocarcinoma (Fig. 6F). These observations indicated that miR-378a was able to alleviate colonic hyperplasia and adenocarcinoma. H&E staining revealed that CRC tumors were well differentiated with an acinar pattern in MC-miR378-treated AOM/DSS mice, whereas CRC tumors in control AOM/DSS mice exhibited poor differentiation, indicating the strong inhibitory effect of miR-378a on colon cancer development (Fig. 6D). Mechanistically, miR-378a led to reduced mRNA levels of FoxQ1, c-Myc and Odc1, enzyme activity of ODC and polyamine synthesis (Fig. 7A-C). K67 staining (general marker of cell proliferation) confirmed the inhibitory effect of miR-378a on growth of colon cancer, which was reflected by a significant reduction in proliferating colon cells (Fig. 7D-E). In summary, miR-378a maintains an appropriate level of polyamine by precisely fine tuning polyamine synthesis, which subsequently prevents CRC development.

Fig. 6
figure 6

miR-378a significantly prevented CRC development in AOM/DSS mice. A Scheme for AOM/DSS-induced colon carcinogenesis in mice. Mice were kept on normal chow. Five-weeks old mice were given AOM, followed by 1% DSS in water for 4 days. At 13 weeks of age, mice were injected with MC-miR378-MM (n = 6, control) or MC-miR378 (n = 6) weekly for 10 weeks. B Diagram of miR-378a mini-circle expression vector (MC-miR378). C Representative photos of CRC tumors in mice treated with MC-miR378 and MC-miR378-MM. Black arrows indicate colon tumors. Both total tumor number and tumors with the size of ≥ 2 mm were reduced in AOM/DSS mice treated with MC-miR378. D H&E staining of colon from two groups of mice. Red arrowhead: acinar regions; green arrowhead: inflammation regions; and blue arrowhead: hyperplasia regions. E, F Scores of hyperplasia, inflammation and adenocarcinoma in AOM/DSS mice treated with MC-miR378 or MC-miR378-MM. Data represent mean ± SEM. **p < 0.01 and ***p < 0.001 (Fig. 6C, E–F: two-tailed student’s t test)

Full size image
Fig. 7
figure 7

miR-378a reduced enzyme activity of ODC and proliferation of colon cells in AOM/DSS mice. A Levels of miR-378a and mRNA levels of FoxQ1, c-Myc and Odc1 in AOM/DSS mice injected with MC-miR378 and MC-miR378-MM. B Reduced enzyme activity of ODC in AOM/DSS mice treated with MC-miR378. C Levels of putrescine (PUT), spermidine (SPD) and spermine (SPM) in AOM/DSS mice injected with MC-miR378 or MC-miR378-MM (control). D, E A significant reduction in proliferation of colon cells in AOM/DSS mice treated with MC-miR378, as revealed by Ki67 staining. Data represent mean ± SEM. **p < 0.01 and ***p < 0.001 (Fig. 7A-E: two-tailed student’s t test)

Full size image

Discussion

Both c-MYC signaling and polyamine synthesis are frequently activated in human cancers, especially during the early-stage development of CRC [29, 30]. Targeting oncogenic c-MYC and ODC1 has emerged as a strategy for cancer treatment [31, 32]. However, their clinical applications have been impeded due to serious adverse effects and low effectiveness. Advance in CRC treatment requires the development of new, specific, and highly targeted therapies. Recent studies of miRNAs brought polyamine metabolism and c-MYC signaling back to the attention, providing a potential correlation between miRNAs and c-MYC-ODC1 axis in tumorigenesis. In this study, we uncover a significant reduction in miR-378a that inhibits c-MYC signaling and ODC1-mediated polyamine biosynthesis, highlighting the role of miR-378a as a potent inhibitor of abnormal polyamine synthesis and CRC.

This study provides several novel insights into the biology and therapeutic relevance of miR-378a for the treatment of CRC. First, we established that miR-378a was significantly down-regulated in CRC tumors of patients and mice, suggesting that our findings could be applied to patients. miRNAs are naturally-occurring noncoding RNAs that fine tune expression of their targets [33]. This characteristic of miRNAs led to our speculation that miR-378 was able to precisely maintain level of polyamine and represents a unique and novel therapeutic agent with less adverse effects compared to chemically synthesized ODC1 and c-MYC inhibitors.

Second, miR-378a served as a potent inhibitor of polyamine biosynthesis by directly targeting ODC1 and blocking the FOXQ1-MYC-ODC1 axis. In addition to directly inhibiting ODC1, miR-378a also exerted its inhibitory effect on ODC1 by blocking the FOXQ1-MYC axis, suggesting that miR-378a could modulate polyamine synthesis at multiple layers. An increase in enzymes controlling polyamine synthesis such as ODC1 leads to increased polyamines, which are thought to maintain the transformed phenotype and tumor development [9]. Intriguingly, extravagant polyamine itself could exert a major damaging effect on cell viability [34], suggesting that precisely maintaining polyamine level is required for normal growth of cells and prevention of transformation of normal cells. MiR-378a is such a fine tuner to maintain an appropriate level of polyamine. In CRC cells, polyamine level is much higher than in normal cells due to the upregulation of ODC1 from oncogenic signaling [5, 6]. As such, overexpression of miR-378a prevents polyamine level from extending beyond the toxic threshold, and still maintain a relatively reasonable level of polyamine favorable to support normal growth of cells. Thus, a potent inhibitor of ODC1 could potentially lead to a polyamine level that is lower than what is needed for normal grow of cells, providing a potential explanation of serious adverse effects of chemically-synthesized ODC inhibitors. Taken together, our findings highlight an important role of miR-378a in preventing imbalance of polyamine in colon cells.

Third, our study revealed a novel function of FOXQ1 that promotes abnormal activation of c-MYC signaling and polyamine synthesis in CRC. FOXQ1 is one of the FOX gene family and contains the core DNA binding domain, whereas its flanking wings are important for its sequence specificity [35]. FOXQ1 activates or represses transcription [36]. It is well described regarding the role of FOXQ1 in regulating hair follicle differentiation [37]. Recently, overexpression of FOXQ1 is observed in CRC [38]. However, the underlying mechanism by which FOXQ1 promotes CRC is poorly characterized. Our findings for the first time revealed that FOXQ1 activated c-MYC signaling and polyamine synthesis, thereby driving CRC development. Indeed, survival analysis revealed a significant correlation between high FOXQ1 mRNA and poor survival in CRC (Additional file 1: Fig. S5). We have established that c-MYC and ODC1 are downstream effectors of FOXQ1 during the development of CRC. Aberrant expression of c-MYC and ODC1 was observed in CRC (Fig. 1). Thus, FOXQ1-mediated activation of c-MYC signaling and polyamine synthesis is an intrinsic molecular phenotype of colon cancer.

Finally, our results indicate that miR-378a, via simultaneously inhibiting ODC1, FOXQ1 and c-MYC pathways, represents a new therapeutic strategy for the treatment of CRC. As revealed by the Cancer Genome Atlas, activation of MYC-dependent transcription has been observed in nearly all types of CRC [10]. c-MYC functions as a master transcription factor in various biological processes by regulating many target genes, and excessive activation of c-MYC is one of the most prevalent oncogenic events in human cancers [39, 40]. In addition of c-MYC amplification, FOXQ1 was identified as another activator of c-MYC signaling. We showed that FoxQ1 was increased in AOM/DSS mice. Notably, overall level of FOXQ1 in 275 CRC patients was 8 times higher than that in 41 normal individuals (Fig. 3C). Overexpression of FOXQ1 drove proliferation and growth of CRC cells. All these findings established both c-MYC and FOXQ1 were ideal therapeutic targets for CRC. Intriguingly, we established that FOXQ1 was a transcription activator of c-MYC, while FOXQ1 was a direct target of miR-378a, indicating that miR-378a, in general, is an inhibitor of FOXQ1-cMYC cascade that is activated in CRC. Taken together, miR-378a is a master regulator to maintain normal level of polyamine by preventing abnormal activation of c-MYC and FOXQ1 signaling. MiR-378a-based therapeutics represents a promising approach to tailor CRC therapy with minimal toxicity.

Material and methods

Human CRC samples

Collection of human CRC tumors and normal mucosa were described in our precious publication [20]. All CRC and non-cancerous tissue specimens were evaluated by an experienced pathologist.

AOM/DSS CRC mouse model

Wild-type male Balb/c mice at five-weeks old (Jackson Laboratory, n = 6) kept on a normal chow diet (SD) (Open Source D12450B: 10% Kcal fat) were injected with 10 mg/kg body weight of AOM (Azoxymethane) via intraperitoneal injection, followed by 2% DSS (Dextran Sodium Sulfate) in drinking water for 4 days. At 23 weeks of age, all mice developed CRC as described [27]. Growth of colon tumor was monitored with a VEVO 770 ultrasound micro-imaging system designed for use with small animals. Colons were collected for further analysis.

miRNA profiling of CRC tumors in AOM/DSS mice

miRNA profiling data of CRC tumors of AOM/DSS mice were downloaded from Gene Expression Omnibus (GSE44988) [21]. GeneSpring (Agilent Technologies Genomics) was used to analyze miRNA profiles of three normal colon samples (wild-type mice) and three CRC tumor samples (AOM/DSS mice). Differentially expressed miRNAs were defined by a log-scale ratio ≤ 1 between paired samples with a p < 0.05. These criteria identified 54 differentially expressed miRNAs in CRC tumors of AOM/DSS mice. To identify miRNAs that are differentially-expressed in CRC tumors of both AOM/DSS mice and CRC patients, we used Microsoft Access 2016 to compare 54 differentially-expressed miRNAs in AOM/DSS mice with 37 differentially-expressed miRNAs in CRC patients in our previous study [20]. This correlation analysis identified four miRNAs that are reduced in CRC tumors of both AOM/DSS mice and CRC patients (Fig. 1B).

Pathway array analysis

To identify miR-378a-regulated signaling pathways, we used Oligo GEarray Signal Transduction PathwayFinder MicroArray (Qiagen) to profile genes regulated by miR-378a in murine CRC cell line CT26.WT. Briefly, CT26.WT cells were transfected with miR-378a mimic or scramble control. 48 h post transfection, total RNA was isolated from two groups of CT26.WT cells using RNeasy Mini Kit (Qiagen). Synthesis of complimentary DNA, biotin labelling of cRNA, and hybridization of Mouse Oligo GEArray Mouse Signal Transduction PathwayFinder Microarray (OMM-014) were performed as described previously [41].

Preparation of mini-circle expression vectors for miR-378a

Construction of mini-circle expression vector of miR-378a and preparation of mini-circles were performed based on the protocol as described previously [42]. Briefly, the murine genomic region containing the precursor of miR-378a was cloned into mini-circle vectors (System Biosciences, Cat. MN511A-1), referred to as MC-miR378. To further ascertain that reduced growth of CRC in MC-miR378-injected mice is due to miR-378a overexpression rather than toxicity caused by miR-378a, we generated a control scramble that differs from miR-378a in four mismatched base pairs (MC-miR378-MM). Mini-circles were prepared based on the manufacturer’s instructions.

MC-miR378 treatment of AOM/DSS mice

Two groups of AOM/DSS mice was injected with either MC-miR378 (n = 6) or MC-miR378-MM (control, n = 6) at a dose of 1.5 μg/g MC-miR378 or MC-miR378-MM complexed with in vivo-jetPEI (Polyplus Transfection, Strasbourg, France) weekly for 10 weeks via tail vein injection. After 10 weeks of MC-miR378 treatment, colons were collected for further analysis.

Cell culture and transfection

Colorectal cancer cell lines CT26.WT, HCT116 and DLD-1 (ATCC, Manassas, VA) were cultured in DMEM containing 10% FBS. All cells were split prior to establishment of confluence and incubated in a humidified incubator with 5% CO2 at 37℃. Lipofectamine 3000 (Invitrogen) was used to cell transfection following manufacturer’s protocol.

Colony formation assay in soft agar

HCT116 or DLD-1 cells was plated in triplicate at 10,000 cells/mL in 0.35% Seaplaque agarose gel (Lonza) using 24 well plates. After two weeks, colonies were stained with crystal violet, photographed and counted.

Cell viability assay

HCT116 or DLD-1 cells was plated in 96-well plates at 1,000/well. 48 h post transfection, cell viability was determined via MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5- Diphenyltetrazolium Bromide) and detected absorbance at OD 570 nm by BioTek Synergy HTX multi-mode reader. The experiment was performed in triplicate.

Apoptosis assay

Annexin V and propidium iodide (PI) (BD Pharmingen, San Diego, CA) were used to assess and quantify apoptosis of DLD-1 and HCT116 cells based on the manufacturer's protocols. 48 h after transfection, DLD-1 or HCT116 cells were detached by accutase (Invitrogen) and washed with cold PBS (pH 7.4). After five minutes of centrifuge at 2000 × g, cell were re-suspended in 100 μL of binding buffer (10 mM HEPES/NaOH, pH 7.4; 140 mM NaCl; and 2.5 mM CaCl2). The cell suspension with 1 × 105 cells (100 μL) was then incubated with 5 μL of Alexa Fluor® 488 Annexin V and 1 μL of 100 μg/mL PI at room temperature in the dark for 15 min. After incubation, add 400 μL of 1 × Annexin-binding buffers, mix gently and then analyze with LSR II H1160 flow cytometer and analyzed in CellQuest software (BD Biosciences, San Diego, CA).

Wound healing assay

24 h post transfection of DLD-1 or HCT116 cells, 200 μL plastic filter tip was used to make vertical scratches (a ‘wound’ of approximately 400 μm in diameter) and the medium was exchanged with fresh DMEM containing 2% FBS. Migration of cells were evaluated under an inverted microscope at 0, 24 and 48 h.

Activity assay of ODC

Enzymatic activity of ODC1 was measured using CB6/DSMI method (Cucurbit[6]uril Hydrate, CB6 and trans-4-[4-(Dimethylamino)styryl]-1-methylpyridinium iodide, DSMI based on the manufacturer’s instruction (Catalog Number: 10316-OD) to measure the ability of ODC to convert ornithine to putrescine. L-ornithine monohydrochloride (Sigma, Catalog # O2375) was used as the substrate.

Statistical analysis

GraphPad Prism Software® was used to perform statistical analysis. Data derived from cell-line experiments were presented as mean ± SEM and the statistical significance was evaluated via a two-tailed Student t test. ANOVA (Analysis of variance) was used to measure statistical difference among multiple groups. All the experiments were repeated at least three times. p < 0.05 was considered to be statistically significant.

Availability of data and materials

All data relevant to the study are included in the article or uploaded as supplementary information. Materials are available as reasonably requested.

References

  1. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017;67(3):177–93.

    Article  PubMed  Google Scholar 

  2. Maida M, Macaluso FS, Ianiro G, Mangiola F, Sinagra E, Hold G, et al. Screening of colorectal cancer: present and future. Expert Rev Anticancer Ther. 2017;7(12):1131–46.

    Article  Google Scholar 

  3. Weitz J, Koch M, Debus J, Hohler T, Galle PR, Buchler MW. Colorectal cancer. Lancet. 2005;365(9454):153–65.

    Article  PubMed  Google Scholar 

  4. Tariq K, Ghias K. Colorectal cancer carcinogenesis: a review of mechanisms. Cancer Biol Med. 2016;13(1):120.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gerner EW, Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 2004;4(10):781–92.

    Article  CAS  PubMed  Google Scholar 

  6. Casero RA, Stewart TM, Pegg AE. Polyamine metabolism and cancer: treatments, challenges and opportunities. Nat Rev Cancer. 2018;18(11):681–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zell JA, Ziogas A, Ignatenko N, Honda J, Qu N, Bobbs AS, et al. Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res. 2009;15(19):6208–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Guo Y, Ye Q, Deng P, Cao Y, He D, Zhou Z, et al. Spermine synthase and MYC cooperate to maintain colorectal cancer cell survival by repressing Bim expression. Nat Commun. 2020;11(1):1–16.

    Article  Google Scholar 

  9. Arruabarrena-Aristorena A, Zabala-Letona A, Carracedo A. Oil for the cancer engine: The cross-talk between oncogenic signaling and polyamine metabolism. Sci Adv. 2018;4(1):1–11.

    Article  Google Scholar 

  10. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330.

    Article  Google Scholar 

  11. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci. 1993;90(16):7804–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Babbar N, Gerner EW. Targeting polyamines and inflammation for cancer prevention. Clin Cancer Prevent. 2011. https://doi.org/10.1007/978-3-642-10858-7_4.

    Article  Google Scholar 

  13. Raj K, Zell J, Rock C, McLaren C, Zoumas-Morse C, Gerner E, et al. Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer. 2013;108(3):512–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Laukaitis CM, Gerner EW. DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol. 2011;25(4):495–506.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Filipowicz W, Bhattacharyya S, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102–14.

    Article  CAS  PubMed  Google Scholar 

  16. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005;120(1):15–20.

    Article  CAS  PubMed  Google Scholar 

  17. Pellatt DF, Stevens JR, Wolff RK, Mullany LE, Herrick JS, Samowitz W, et al. Expression profiles of miRNA subsets distinguish human colorectal carcinoma and normal colonic mucosa. Clin Transl Gastroenterol. 2016;7(3): e152.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Liang G, Li J, Sun B, Li S, Lü L, Wang Y, et al. Deep sequencing reveals complex mechanisms of microRNA deregulation in colorectal cancer. Int J Oncol. 2014;45(2):603–10.

    Article  CAS  PubMed  Google Scholar 

  19. Coppedè F. The role of epigenetics in colorectal cancer. Expert Rev Gastroenterol Hepatol. 2014;8(8):935–48.

    Article  PubMed  Google Scholar 

  20. Sarver AL, French AJ, Borralho PM, Thayanithy V, Oberg AL, Silverstein KA, et al. Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states. BMC Cancer. 2009;9(1):401.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gao Y, Li X, Yang M, Zhao Q, Liu X, Wang G, et al. Colitis-accelerated colorectal cancer and metabolic dysregulation in a mouse model. Carcinogenesis. 2013;34(8):1861–9.

    Article  CAS  PubMed  Google Scholar 

  22. Chen Z-Y, He C-Y, Kay MA. Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo. Hum Gene Ther. 2005;16(1):126–31.

    Article  CAS  PubMed  Google Scholar 

  23. Yang J-H, Li J-H, Shao P, Zhou H, Chen Y-Q, Qu L-H. starBase: a database for exploring microRNA–mRNA interaction maps from Argonaute CLIP-Seq and Degradome-Seq data. Nucleic Acids Res. 2011;39(suppl 1):D202–9.

    Article  CAS  PubMed  Google Scholar 

  24. Cartharius K, Frech K, Grote K, Klocke B, Haltmeier M, Klingenhoff A, et al. MatInspector and beyond: promoter analysis based on transcription factor binding sites. Bioinformatics. 2005;21(13):2933–42.

    Article  CAS  PubMed  Google Scholar 

  25. Abba M, Patil N, Rasheed K, Nelson LD, Mudduluru G, Leupold JH, et al. Unraveling the role of FOXQ1 in colorectal cancer metastasis. Mol Cancer Res. 2013;11(9):1017–28.

    Article  CAS  PubMed  Google Scholar 

  26. Staton AA, Giraldez AJ. Use of target protector morpholinos to analyze the physiological roles of specific miRNA-mRNA pairs in vivo. Nat Protoc. 2011;6(12):2035–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. De Robertis M, Massi E, Poeta ML, Carotti S, Morini S, Cecchetelli L, et al. The AOM/DSS murine model for the study of colon carcinogenesis: from pathways to diagnosis and therapy studies. J Carcinog. 2011;10:1–9.

    Google Scholar 

  28. Rosenberg DW, Giardina C, Tanaka T. Mouse models for the study of colon carcinogenesis. Carcinogenesis. 2009;30(2):183–96.

    Article  CAS  PubMed  Google Scholar 

  29. Wallace HM, Caslake R. Polyamines and colon cancer. Eur J Gastroenterol Hepatol. 2001;13(9):1033–9.

    Article  CAS  PubMed  Google Scholar 

  30. Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, et al. c-myc oncogene expression in colorectal cancer. Cancer. 1987;59(7):1289–95.

    Article  CAS  PubMed  Google Scholar 

  31. Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3(1):1–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gerner EW, Bruckheimer E, Cohen A. Cancer pharmacoprevention: targeting polyamine metabolism to manage risk factors for colon cancer. J Biol Chem. 2018;293(48):18770–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.

    Article  CAS  PubMed  Google Scholar 

  34. Pignatti C, Tantini B, Stefanelli C, Flamigni F. Signal transduction pathways linking polyamines to apoptosis. Amino Acids. 2004;27(3–4):359–65.

    Article  CAS  PubMed  Google Scholar 

  35. Overdier DG, Porcella A, Costa RH. The DNA-binding specificity of the hepatocyte nuclear factor 3/forkhead domain is influenced by amino-acid residues adjacent to the recognition helix. Mol Cell Biol. 1994;14(4):2755–66.

    CAS  PubMed  PubMed Central  Google Scholar 

  36. Wang P, Lv C, Zhang T, Liu J, Yang J, Guan F, et al. FOXQ1 regulates senescence-associated inflammation via activation of SIRT1 expression. Cell Death Dis. 2017;8(7):e2946–e2946.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hong HK, Noveroske JK, Headon DJ, Liu T, Sy MS, Justice MJ, et al. The winged helix/forkhead transcription factor Foxq1 regulates differentiation of hair in satin mice. Genesis. 2001;29(4):163–71.

    Article  CAS  PubMed  Google Scholar 

  38. Kaneda H, Arao T, Tanaka K, Tamura D, Aomatsu K, Kudo K, et al. FOXQ1 is overexpressed in colorectal cancer and enhances tumorigenicity and tumor growth. Can Res. 2010;70(5):2053–63.

    Article  CAS  Google Scholar 

  39. Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90.

    Article  CAS  PubMed  Google Scholar 

  41. Bickler PE, Fahlman CS. Expression of signal transduction genes differs after hypoxic or isoflurane preconditioning of rat hippocampal slice cultures. J Am Soc Anesthesiol. 2009;111(2):258–66.

    Article  CAS  Google Scholar 

  42. Wu H, Tao J, Li X, Zhang T, Zhao L, Wang Y, et al. MicroRNA-206 prevents the pathogenesis of hepatocellular carcinoma by modulating expression of met proto-oncogene and cyclin-dependent kinase 6 in mice. Hepatology. 2017;66(6):1952–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was in part supported by Research Scholar Grant (ISG-16-210-01-RMC) from the American Cancer Society.

Author information

Author notes

  1. Ningning Liu and Tianpeng Zhang contributed equally to this work

Authors and Affiliations

  1. Department of Medicine, University of Minnesota, Minneapolis, MN, 55455, USA

    Ningning Liu, Tianpeng Zhang, Clifford J. Steer & Guisheng Song

  2. Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, 55455, USA

    Ningning Liu, Tianpeng Zhang & Guisheng Song

  3. Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, 516 Delaware Street SE, Minneapolis, MN, 55455, USA

    Guisheng Song

Authors
  1. Ningning Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tianpeng Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clifford J. Steer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Guisheng Song
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Acquisition of data: LN and ZT. SCJ: Analysis and interpretation of data. SG: Obtaining funding, study supervision, study concept and design and initial drafting of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Guisheng Song.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Department of Medicine, University of Minnesota. All procedures involving mice were approved by the Institutional Animal Care Committee at the University of Minnesota.

Consent for publication

The publication of this manuscript has been approved by all authors.

Competing interests

The authors involved in this study declare that they have nothing to disclose regarding funding or conflict of interest with respect to this manuscript.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Fig. S1.

mRNA levels of TFRC, MDM2 and VCAM1. (A, B, C) No significant change in mRNA levels of TFRC, MDM2 and VCAM1 was observed between 275 CRC tumors versus 41 normal colon tissue samples. GEPIA2 was used to analyze TCGA and GTEx datasets. NS: no significance. Fig. S2. miR-378a failed to bind to the 3’UTR of c-MYC. (A, B) Luciferase activities of the reporter constructs containing the 3’UTR of c-MYC after treatment with MC-miR-378 or anti-sense oligo (ASO). HCT116 cells transfected with the empty luciferase reporter vector and MC-miR378-MM or scramble served as control. NS: no significance. Data represent mean ± SEM. two-tailed student t test. ns: no significance. Fig. S3. MC-miR378 injection into mice led to increased miR-378a in the colon. (A) mRNA levels of FOXQ1 and ODC1 in DLD-1 cells transfected with MC-miR-378a or MC-miR389-MM (two-tailed student t test). (B) Levels of PUT, SPD and SPM in DLD-1 levels treated with MC-miR378 or MC-miR378-MM (two-tailed student t test). (C-D) mRNA levels of FOXQ1 and ODC1 and levels of PUT, SPD and SPM in DLD-1 cells transfected with either MC-miR378-MM (control), MC-miR378, or a combination of MC-miR378 and TPs of ODC1 and FOXQ1. Data represent mean ± SEM. *p < 0.05, **p < 0.01 (two-way ANOVA test). Fig. S4. Level of miR-378a in colons of mice treated with MC-miR378. Increased miR-378a in colons of mice treated with MC-miR378 (n=6) compared to the mice treated with MC-miR378-MM (n=6). Data represent mean ± SEM. ***p < 0.001 (two-tailed student t test). Fig. S5. Kaplan–Meier survival curve analysis of FOXQ1 for overall survival of CRC patients. Level of FOXQ1 was negatively correlated with overall survival of CRC patients. GEPIA2 was used for survival analysis of CRC patients in the TCGA dataset.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, N., Zhang, T., Steer, C.J. et al. MicroRNA-378a-3p prevents initiation and growth of colorectal cancer by fine tuning polyamine synthesis. Cell Biosci 12, 192 (2022). https://doi.org/10.1186/s13578-022-00930-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13578-022-00930-3

Keywords

  • Ornithine decarboxylase inhibitor
  • c-Myc signaling
  • Non-coding RNA

Cell & Bioscience

ISSN: 2045-3701

Contact us